<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (PTLD) are a life-threatening complication of solid organ transplantation or, more rarely, hematopoietic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>PTLD generally display involvement of extranodal sites, aggressive histology and aggressive clinical behavior </plain></SENT>
<SENT sid="3" pm="."><plain>The molecular pathogenesis of PTLD involves <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> by oncogenic viruses, namely EBV, as well as genetic or epigenetic alterations of several cellular genes </plain></SENT>
<SENT sid="4" pm="."><plain>At variance with <z:hpo ids='HP_0002665'>lymphoma</z:hpo> arising in immunocompetent hosts, whose genome is relatively stable, a fraction of PTLD are characterized by microsatellite instability as a consequence of defects in the DNA mismatch repair mechanism </plain></SENT>
<SENT sid="5" pm="."><plain>Apart from microsatellite instability, molecular alterations of cellular genes recognized in PTLD include alterations of cMYC, BCL6, TP53, DNA hypermethylation, and aberrant somatic hypermutation of protooncogenes </plain></SENT>
<SENT sid="6" pm="."><plain>The occurrence of IGV mutations in the overwhelming majority of PTLD documents that <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> targets germinal centre (GC) B-cells and their descendants both in EBV-positive and EBV-negative cases </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis of phenotypic markers of B-cell histogenesis, namely BCL6, MUM1 and CD138, allows further distinction of PTLD histogenetic categories </plain></SENT>
<SENT sid="8" pm="."><plain>PTLD expressing the BCL6+/MUM1+/-/CD138- profile reflect B-cells actively experiencing the GC reaction, and comprise diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) <z:e sem="disease" ids="C1516391" disease_type="Neoplastic Process" abbrv="">centroblastic</z:e> and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>PTLD expressing the BCL6-/MUM1+/CD138- phenotype putatively derive from B-cells that have concluded the GC reaction, and comprise the majority of <z:e sem="disease" ids="C1301361" disease_type="Neoplastic Process" abbrv="">polymorphic PTLD</z:e> and a fraction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>A third group of PTLD is reminiscent of post-GC and preterminally differentiated B-cells that show the BCL6-/MUM1+/CD138+ phenotype, and are morphologically represented by either <z:e sem="disease" ids="C1301361" disease_type="Neoplastic Process" abbrv="">polymorphic PTLD</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> <z:e sem="disease" ids="C1521815" disease_type="Neoplastic Process" abbrv="">immunoblastic</z:e> </plain></SENT>
</text></document>